Addition of chemoradiotherapy to palliative chemotherapy in de novo metastatic nasopharyngeal carcinoma: a real-world study.
Addition of chemoradiotherapy to palliative chemotherapy in de novo metastatic nasopharyngeal carcinoma: a real-world study.
复制标题
姑息化疗联合放化疗治疗新发转移性鼻咽癌：一项真实世界研究
DOI：
10.1186/s12935-022-02464-7
复制
发表时间：
2022-01-24
影响因子：
5.8
通讯作者：
Xia YF
中科院分区：
文献类型：
--
作者：
Zheng SH;Wang YT;Liu SR;Huang ZL;Wang GN;Lin JT;Ding SR;Chen C;Xia YF
确定在NOKO转移性鼻咽癌（MNPC）患者姑息化疗（PCT）后局部放疗（RT）期间是否需要进行化疗。
在我们医院共有746例MNPC患者，在他们的医院中进行了回顾，其中有355例患者接受了PCT，其次是RT。通过Kaplan-Meier方法和对数秩比例的模型，LRPFS）和拆卸无进展生存率（DPF）。分析，可靠性得分匹配和亚组分析用于解决混杂问题。
在我们的研究中包括的患者中，192例PCT（PCT+RT）单独接受了放射疗法，而PCT后163例（PCT+CCRT）同时进行了化学放疗（PCT+CCRT）。 OS，53.0 vs 36.2％； p = 0.004。 （p = 0.034）和中位数为29.4和18.7个月（p = 0.052）。 PCT的4–6个周期或与单药铂进行同时进行化学疗法与匹配的队列中的显着生存率有关（5年OS率，分别为60.4或57.4％），在评估生存的1年的患者时，组之间的生存差异仍然很大（P≉= 0.028）。
MNPC的最佳治疗策略是PCT的组合，然后是同时进行的化学疗法。
在线版本包含的补充材料可获得10.1186/s12935-022-02464-7。
To determine whether concurrent chemotherapy is necessary during locoregional radiotherapy (RT) after palliative chemotherapy (PCT) in patients with de novo metastatic nasopharyngeal carcinoma (mNPC). A total of 746 patients with mNPC from 2000 to 2017 at our hospital were retrospectively reviewed. Among them, 355 patients received PCT followed by RT. Overall survival (OS) and progression-free survival (PFS), including locoregional progression-free survival (LRPFS) and distant progression-free survival (DPFS) were estimated with the Kaplan–Meier method and log-rank test. Cox proportional-hazards models, landmark analyses, propensity score matching, and subgroup analyses were used to address confounding. Of the patients included in our study, 192 received radiotherapy alone after PCT (PCT + RT), and 163 received concurrent chemoradiotherapy after PCT (PCT + CCRT). The prognosis of PCT + CCRT was significantly better than that of PCT + RT (5 year OS, 53.0 vs 36.2%; P = 0.004). After matching, the 5 year OS rates of the two groups were 55.7 and 39.0%, respectively (P = 0.034) and the median DPFS were 29.4 and 18.7 months, respectively (P = 0.052). Multivariate Cox regression analysis indicated that PCT + CCRT was an independent favorable prognostic factor (P = 0.009). In addition, conducting concurrent chemoradiotherapy after 4–6 cycles of PCT or conducting concurrent chemotherapy with single-agent platinum was associated with significant survival benefit in the matched cohort (5 year OS rate, 60.4 or 57.4%, respectively). The survival difference between groups remained significant when evaluating patients who survived for ≥ 1 year (P = 0.028). The optimal treatment strategy of mNPC is the combination of PCT followed by concurrent chemoradiotherapy. More specifically, concurrent chemoradiotherapy with single-agent platinum after 4–6 cycles of PCT is suggested. The online version contains supplementary material available at 10.1186/s12935-022-02464-7.
登录
查看更多内容
影响因子：
168.9
作者：
Mickisch, GHJ;Garin, A;Sylvester, R
通讯作者：
Sylvester, R
影响因子：
45.3
作者：
Hsu, Chiun;Lee, Se-Hoon;Hansen, Aaron R.
通讯作者：
Hansen, Aaron R.
影响因子：
45.3
作者：
Ma, Brigette B. Y.;Lim, Wan-Teck;Chan, Anthony T. C.
通讯作者：
Chan, Anthony T. C.
开发一个预后模型来确定新发转移性鼻咽癌合适的最终放射治疗候选者：一项真实世界研究。
DOI：
10.1016/j.ijrobp.2020.08.045
发表时间：
2021-01-01
影响因子：
7
作者：
Li, Wang-Zhong;Lv, Shu-Hui;Liu, Guo-Ying;Liang, Hu;Guo, Xiang;Lv, Xing;Liu, Kui-Yuan;Qiang, Meng-Yun;Chen, Xi;Gu, Sophie Z.;Xie, Chang-Qing;Xia, Wei-Xiong;Xiang, Yan-Qun
通讯作者：
Xiang, Yan-Qun
影响因子：
--
作者：
Shen LJ;Wang SY;Xie GF;Zeng Q;Chen C;Dong AN;Huang ZM;Pan CC;Xia YF;Wu PH
通讯作者：
Wu PH